ArticleFrontiers in oncology2026
Dosimetric impact of two multileaf collimator systems in simultaneous integrated boost volumetric modulated arc therapy for lymph node metastases in stage IIIC cervical cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Patients with FIGO stage IIIC cervical cancer frequently present with complex lymph node metastases (LNM), and proximity to multiple organs at risk (OARs) poses challenges for volumetric modulated arc therapy with simultaneous integrated boost (SIB-VMAT) planning. This study compared orthogonal dual-layer and parallel dual-layer multileaf collimator (MLC) systems, assessing dosimetric performance to inform clinical practice in complex nodal boost scenarios. Methods: This retrospective planning study included 45 patients with FIGO 2018 stage IIIC cervical cancer who underwent SIB-VMAT between February 2022 and March 2024. Patients were stratified according to LNM distribution into unilateral pelvic, bilateral pelvic, and para-aortic subgroups (n = 15 per subgroup). The planning target volume (PTV) received a prescribed dose of 45-50.4 Gy in 25-28 fractions, while metastatic lymph nodes (PGTVnd) received 54-63 Gy using the SIB technique. For each patient, SIB-VMAT plans were generated using an alpha orthogonal dual-layer MLC (α-MLC) system and a parallel dual-layer MLC (p-MLC) system under identical planning objectives and dose constraints. Dosimetric parameters of target volumes and OARs were analyzed to assess planning feasibility and system-dependent planning characteristics. Each system was evaluated within its clinically commissioned treatment planning environment to reflect real-world clinical practice. Results: Clinically acceptable target coverage was achieved with both MLC systems across all LNM subgroups. Particularly in patients with bilateral pelvic LNM, the α-MLC system demonstrated slightly improved dose gradient control for the PTV, reflected by a lower gradient index (p < 0.05). Other target-related dosimetric parameters for the PTV and PGTVnd, including D Conclusion: Both MLC systems achieved clinically acceptable target coverage across all LNM subgroups, while the α-MLC system demonstrated superior OAR sparing. These system-level differences may inform equipment selection and planning strategies in challenging nodal boost scenarios for advanced cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.